Blockchain Registration Transaction Record

Oncotelic's Injectable Breast Cancer Drug Gets Australian Trial Approval

Oncotelic Therapeutics receives Australian ethics approval for Phase 1 trial of injectable Everolimus for breast cancer using innovative Deciparticle technology for improved drug absorption.

This development matters because breast cancer remains one of the most prevalent cancers worldwide, affecting millions of patients who often face limited treatment options and significant side effects from current therapies. The innovation of converting an established oral cancer drug into an injectable form with potentially 90% better absorption could dramatically improve treatment outcomes and quality of life for patients. Current oral Everolimus (Afinitor) is used in various cancer treatments but its low absorption rate limits effectiveness and requires higher doses that increase side effects. If successful, this intravenous delivery approach could set a new standard for how existing cancer drugs are reformulated, potentially extending to other medications beyond breast cancer treatment. For the pharmaceutical industry, this represents an important advancement in drug delivery technology that could breathe new life into established therapeutics, offering improved efficacy without the lengthy development process of entirely new drugs.